Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by PoorOpinionon Nov 03, 2018 1:36pm

111 Views

Post# 28919346

RE:RE:RE:RE:RE:Taimed up.

(All numbers In NT$ thousand)

So if we take that this months sales include just the adjustment between estimated NSP and actual NSP (i.e. no increased stocking) then here's my (possibly wonky) maths.

Total aggregate sales before this month 111,745
Estimated discount was 30%, actual discount now is 25%
Extra invoiced for this change for previous months = 7,978

Actual monthly sales this month 53,402-7978= 45,424

But this number is at the new NSP so to do a direct comparison with the previous month number adjust to 42,397. Previous month was 37,011 so that would suggest sales grew about 15% MoM. Now my maths may be wonky but that doesnt suggest any space for 'overstocking' if we assume they have continued to gain patients.

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale